Abiopharma

🔍 Fox Mary (Executive)

Company: Lovesac Co (LOVE)

Report Date: 2026-04-15

Detailed Transactions and Holdings:

• Acquired 4,848 shares of Common Stock, $0.00001 par value (Direct)
  Date: 2026-04-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 72,077.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 2,296 shares of Common Stock, $0.00001 par value at $16.65 per share (Direct)
  Date: 2026-04-15 | Code: F | equity_swap_involved: 0 | shares_owned_after: 69,781.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 17,066 shares of Common Stock, $0.00001 par value (Direct)
  Date: 2026-04-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 86,847.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 8,080 shares of Common Stock, $0.00001 par value at $16.65 per share (Direct)
  Date: 2026-04-15 | Code: F | equity_swap_involved: 0 | shares_owned_after: 78,767.00 | transaction_form_type: 4 | Footnotes: F4
• Sold 2,132 shares of Common Stock, $0.00001 par value at $16.65 per share (Direct)
  Date: 2026-04-15 | Code: F | equity_swap_involved: 0 | shares_owned_after: 76,635.00 | transaction_form_type: 4 | Footnotes: F5
• Sold 7,433 shares of Common Stock, $0.00001 par value at $16.65 per share (Direct)
  Date: 2026-04-15 | Code: F | equity_swap_involved: 0 | shares_owned_after: 69,202.00 | transaction_form_type: 4 | Footnotes: F6
• Acquired 77,701 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-15 | Code: A | equity_swap_involved: 0 | shares_owned_after: 77,701.00 | transaction_form_type: 4 | Footnotes: F7, F8, F8
• Acquired 77,701 shares of Restricted Stock Units (Performance-based Vesting) (Derivative)
  Date: 2026-04-15 | Code: A | equity_swap_involved: 0 | shares_owned_after: 77,701.00 | transaction_form_type: 4 | Footnotes: F7, F9, F9
• Sold 4,848 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-15 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F7, F1, F1
• Sold 17,066 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 34,134.00 | transaction_form_type: 4 | Footnotes: F7, F3, F3

Footnotes:

• F1: The reported shares were acquired upon the vesting of the third tranche of time-based restricted stock units ("RSUs") granted on April 15, 2023.
• F2: The reported shares were withheld to satisfy the Reporting Person's tax liability in connection with the settlement of the third tranche of time-based RSUs granted on April 15, 2023. No shares were sold.
• F3: The reported shares were acquired upon the vesting of the first tranche of time-based RSUs granted on April 15, 2025.
• F4: The reported shares were withheld to satisfy the Reporting Person's tax liability in connection with the settlement of the first tranche of time-based RSUs granted on April 15, 2025. No shares were sold.
• F5: The reported shares were withheld to satisfy the Reporting Person's tax liability in connection with the settlement of a portion of the third tranche of performance-based RSUs granted on April 15, 2023. No shares were sold.
• F6: The reported shares were withheld to satisfy the Reporting Person's tax liability in connection with the settlement of a portion of the first tranche of performance-based RSUs granted on April 15, 2025. No shares were sold.
• F7: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
• F8: On April 15, 2026, the Reporting Person received a grant of RSUs which vest in three equal installments on the first, second and third anniversaries of the grant date.
• F9: On April 15, 2026, the Reporting Person received a grant of performance-based RSUs which vest based on the Issuer's achievements with respect to certain pre-established performance targets for the performance period. Once earned, the performance-based RSUs are payable at the end of the three-year performance period.